Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07358715
NA

Liquid Biopsy-Based Pre-Screening to Streamline LDCT Lung Cancer Screening in High-Risk Individuals

Sponsor: National University Hospital, Singapore

View on ClinicalTrials.gov

Summary

This study evaluates the feasibility and cost-effectiveness of using a blood-based liquid biopsy assay as a pre-screening tool before low-dose CT (LDCT) for lung cancer screening. By identifying individuals unlikely to have lung cancer, this approach aims to reduce unnecessary LDCT scans, radiation exposure, and healthcare costs, while improving early detection, particularly among high-risk individuals including never-smokers with a family history of lung cancer.

Official title: A Multimodal Liquid Biopsy-Based Assay as a Pre-Screening Test Before Low Dose CT Thorax (LDCT) to Streamline Lung Cancer Screening in High-Risk Individuals

Key Details

Gender

All

Age Range

21 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

140

Start Date

2024-11-01

Completion Date

2028-12-31

Last Updated

2026-01-22

Healthy Volunteers

Yes

Interventions

DIAGNOSTIC_TEST

Liquid Biopsy (SPOT-MAS Assay)

Blood-based genome-wide DNA methylation assay performed on plasma samples to detect tumor-associated methylation patterns suggestive of lung cancer.

DIAGNOSTIC_TEST

Exosome-Based Liquid Biopsy Assay

Blood-based assay analyzing exosome-associated biomarkers to support early detection of lung cancer.

DIAGNOSTIC_TEST

Low-Dose CT Thorax (LDCT)

Low-dose computed tomography of the thorax performed for lung cancer screening

Locations (1)

National University Hospital Singapore

Singapore, Singapore